Clinical effects of calcium dobesilate combined with insulin in the treatment of elderly patients with diabetic nephropathy in early stage
10.3760/cma.j.issn.1008-6706.2017.24.018
- VernacularTitle:羟苯磺酸钙联合胰岛素治疗老年人早期糖尿病肾病的临床效果观察
- Author:
Huihui FAN
1
;
Jian MA
Author Information
1. 宁波市奉化区人民医院内分泌科
- Keywords:
Diabetic nephropathy;
Enalapril;
Calcium dobesilate
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(24):3746-3749
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effects of calcium dobesilate combined with insulin in the treatment of elderly patients with diabetic nephropathy in early stage.Methods 100 elderly patients with diabetic nephropathy in early stage were chosen,and they were randomly divided into two groups according to the digital table,each group in 50cases.The control group were given benazepril alone,and the observation group were given benazepril combined with calcium dobesilate on the basis of intensive insulin intervention.The levels of FPG,2hPG,Scr,BUN,mAlb,β2-MG,Cys-C and hs-CRP and QOL-C30 scores before and after treatment of the two groups were compared.Results There were no statistically significant differences in the levels of FPG,2hPG after treatment between the two groups(all P ＞0.05).Before treatment,the levels of Scr,BUN,mAlb and β2-MG of the control group were (81.16 ± 18.92) mmol/L,(5.63 ± 1.15) mmol/L,(105.71 ± 21.77) mg/24h,(543.46 ± 74.70) μg/L,respectively,which of the observation group were (81.59 ± 19.04) mmol/L,(5.58 ± 1.13) mmol/L,(106.33 ± 2 L 82) mg/24h,(548.20 ± 75.37) μg/L,respectively.After treatment,the levels of Scr,BUN,mAlb and β2-MG of the control group were (78.35 ± 14.35) mmol/L,(5.17 ± 0.97) mmol/L,(69.84 ± 14.24) mg/24h,(395.56 ±42.38) μg/L,respectively,which of the observation group were (73.10 ± 10.74) mmol/L,(4.63 ± 0.71) mmol/L,(52.92 ± 10.52) mg/24h,(337.89 ± 25.04) μg/L,respectively.The levels of Scr,BUN,mAlb and 32-MG after treatment of the observation group were significantly lower than those of the control group and before treatment (t =2.45,2.66,2.18.2.40;2.82,3.10,2.58.3.34;2.61,3.20;2.66.3.05;all P ＜ 0.05).Before treatment,the levels of Cys-C and hs-CRP of the control group were (1.82 ± 0.67) mg/L,(22.73 ± 6.54) mg/L,respectively,which of the observation group were (1.87 ± 0.70) mg/L,(1.17 ± 0.27) mg/L,respectively.After treatment,the levels of Cys -C and hs-CRP of the control group were (1.59 ± O.50) mg/L,(19.35 ± 5.60) mg,/L,respectively,which of the observation group were (22.58 ± 6.50) mg/L,(15.88 ± 4.03) mg/L,respectively.The levels of Cys-C and hs-CRP after treatment of the observation group were significantly lower than those of the control group and before treatment (t =2.32,2.67;2.85,3.19,2.66,3.02;all P ＜ 0.05).The QOL-C30 scores of the control group before and after treatment were (52.65 ± 7.70) points,(68.29 ± 9.84) points,respectively.The QOL-C30 scores of the observation group before and after treatment were (53.22 ± 7.78)points,(80.53 ± 12.10)points,respectively.The QOL-C30 scores of the observation group after treatment were significantly higher than those of the control group and before treatment (t =2.38,2.78,3.15,all P ＜ 0.05).Conclusion Bigeminy drug regimen assisted with intensive insulin intervention in the treatment of elderly patients with diabetic nephropathy in early stage can efficiently protect renal function,reduce the levels of inflammatory cytokines and is helpful to improve the quality of life.
